IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML
NCT ID: NCT04372433
Last Updated: 2025-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
67 participants
INTERVENTIONAL
2020-09-14
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
NCT04801797
A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia
NCT02287233
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
NCT07075016
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
NCT06611839
Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling
NCT05431257
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation of IO-202
Dose cohorts treated with intravenous (IV) IO-202 monotherapy in ascending doses.
IO-202
IO-202 as monotherapy
Dose Escalation of IO-202 Plus Azacitidine
AZA Dose cohorts treated with intravenous (IV) IO-202 in ascending doses plus Azacitidine (IV or SC) on days 1-7 of each 28-day cycle.
IO-202 and Azacitidine
IO-202 and azacitidine combination therapy
Dose Expansion of IO-202 plus Azacitidine AML
To enroll high LILRB4 expression monocytic AML patients refractory to or relapsed after available therapies known to be active in AML.
IO-202 and Azacitidine
IO-202 and azacitidine combination therapy
Dose Expansion of IO-202 plus Azacitidine CMML
To enroll hypomethylating-agent naive CMML patients.
IO-202 and Azacitidine
IO-202 and azacitidine combination therapy
Dose Expansion of IO-202 plus Azacitidine + Venetoclax (Ven)
To enroll newly diagnosed high LILRB4 expression AML patients who are unfit for intensive induction chemotherapy.
IO-202 and Azacitidine + Venetoclax
IO-202 and azacitidine + venetoclax combination therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IO-202
IO-202 as monotherapy
IO-202 and Azacitidine
IO-202 and azacitidine combination therapy
IO-202 and Azacitidine + Venetoclax
IO-202 and azacitidine + venetoclax combination therapy
IO-202 and Azacitidine
IO-202 and azacitidine combination therapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. For the Part 1 Dose-Escalation Phase, patients must be diagnosed with the following:
1. Relapsed or refractory AML with myelomonocytic or monoblastic/monocytic differentiation according to the World Health Organization 2016 criteria and has failed treatment with available therapies known to be active for AML.
2. Relapsed or refractory CMML and has failed treatment with available therapies known to be active for CMML
3. Part 2 Expansion Phase:
1. Relapsed or refractory LILRB4high AML with myelomonocytic or monoblastic/monocytic differentiation and has failed treatment with available therapies known to be active for AML.
2. Hypomethylating-agent naive CMML regardless of LILRB4 expression levels.
3. Newly diagnosed high LILRB4 expression monocytic AML patients considered to be ineligible for standard induction therapy.
4. Patients must be amenable to serial BM aspirates/biopsies and peripheral blood sampling during the study.
5. Patients must be able to understand and willing to sign an informed consent. A legally authorized representative may consent.
6. Patients must have an ECOG performance status of 0 to 2
7. Patients must have adequate hepatic function
8. Patients must have adequate renal function
9. Patients must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer.
10. Patients must be off systemic calcineurin inhibitors for at least 4 weeks prior to study drug treatment.
11. Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to the start of therapy.
Exclusion Criteria
2. Patients who have undergone HSCT within 60 days of the first dose of IO-202.
3. Patients who received systemic anti-cancer therapy or radiotherapy \<7 days prior to their first day of study drug administration (Hydroxyurea or leukapheresis is allowed up to 24 hours prior to the first dose.
4. Patients who received an investigational agent \<7 days prior to their first day of study drug administration.
5. Patients for whom potentially curative anti-cancer therapy is available.
6. Patients who are pregnant or breastfeeding.
7. Patients with uncontrolled, active infection.
8. Patients with known hypersensitivity to any of the components of the IO-202 formulation.
9. Patients with known pulmonary lesions and/or history of pneumonitis or interstitial lung disease.
10. Active known malignancy.
11. Patients with New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) or left ventricular ejection fraction (LVEF) \<40%.
12. Ongoing cardiac dysrhythmias Grade 2 or higher per of NCI CTCAE, Version 5.0, Grade ≥2.
13. Known or suspected hypersensitivity to recombinant proteins.
14. Known active bacterial, viral, and/or fungal infection.
15. Patients with any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol.
16. Patients with clinical signs and/or symptoms suggesting active, uncontrolled central nervous system (CNS) leukemia or known active, uncontrolled CNS leukemia.
17. Patients with immediately life-threatening, severe complications of leukemia.
18. Donor Lymphocyte Infusion within 30 days prior to first IO-202 administration.
19. Current active treatment in another interventional therapeutic clinical study.
20. Chronic systemic corticosteroid treatment with a dose of \>10 mg prednisone/day or dose equivalent.
21. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study.
22. Acute Promyelocytic Leukemia patients or patients with known Philadelphia chromosome (Ph+) positive AML or chronic myelogenous leukemia (CML) blast crisis.
23. Hyperleukocytosis (leukocytes ≥25 x 10e9/L) at first dose of IO-202.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
California Institute for Regenerative Medicine (CIRM)
OTHER
Immune-Onc Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hong Xiang, PhD
Role: STUDY_DIRECTOR
Immune-Onc Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University California, Davis (117)
Davis, California, United States
City of Hope (106)
Duarte, California, United States
University of California, Irvine (107)
Irvine, California, United States
UCLA, Medical Center Division of Hematology/Oncology (119)
Los Angeles, California, United States
Stanford University (114)
Palo Alto, California, United States
University of California, San Francisco (118)
San Francisco, California, United States
University of Colorado, Anschutz Medical Campus (103)
Aurora, Colorado, United States
Winship Cancer Institute of Emory University (105)
Atlanta, Georgia, United States
The University of Chicago (113)
Chicago, Illinois, United States
Weill Cornell Medical College, New York Presbyterian Hospital (110)
New York, New York, United States
Cleveland Clinic, Taussig Cancer Institute (111)
Cleveland, Ohio, United States
Oregon Health and Science University, Center for Hematologic Malignancies (116)
Portland, Oregon, United States
University of Texas Southwestern, Simmons Comprehensive Cancer Center (104)
Dallas, Texas, United States
MD Anderson Cancer Center (101)
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Aribi A, Mannis GN, Madanat YF, Jonas BA, Dunavin N, Roboz GJ, Jeyakumar D, Garcia-Manero G, Liu H, Carraway HE, Saultz JN, Blum W, Schiller G, Huang T, Woodard P, Klencke B, Liao XC, Xiang H, Pollyea DA, DiNardo CD. A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia. Blood Neoplasia. 2025 Jun 9;2(4):100126. doi: 10.1016/j.bneo.2025.100126. eCollection 2025 Nov.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IO-202-CL-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.